51 related articles for article (PubMed ID: 29278885)
1. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
Petrini I; Lencioni M; Vasile E; Fornaro L; Belluomini L; Pasquini G; Ginocchi L; Caparello C; Musettini G; Vivaldi C; Caponi S; Ricci S; Proietti A; Fontanini G; Naccarato AG; Nardini V; Santi S; Falcone A
Cancer Biomark; 2018 Feb; 21(3):731-741. PubMed ID: 29278885
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Human Epidermal Growth Factor Receptor 2 (HER2) Expression Pattern in Gastric Adenocarcinomas in a Nigerian Tertiary Hospital.
Mashor MI; Ezenkwa US; Ogun GO; Ajani MA; Ogunbiyi JO
West Afr J Med; 2024 Mar; 41(3):311-316. PubMed ID: 38788150
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia.
Kasochi C; Julius P; Mweemba I; Kayamba V
Afr Health Sci; 2020 Dec; 20(4):1857-1864. PubMed ID: 34394249
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Carneseca EC; Serrano SV; Viana LS; Nunes JS; Martinez EZ; Santos JS
Gastric Cancer; 2014 Jan; 17(1):76-86. PubMed ID: 23455716
[TBL] [Abstract][Full Text] [Related]
5. The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer.
Li GC; Jia XC; Zhao QC; Zhang HW; Yang P; Xu LL; Pang FN; Sun JB
Medicine (Baltimore); 2020 May; 99(21):e20460. PubMed ID: 32481349
[TBL] [Abstract][Full Text] [Related]
6. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas.
Rajagopal I; Niveditha SR; Sahadev R; Nagappa PK; Rajendra SG
J Clin Diagn Res; 2015 Mar; 9(3):EC06-10. PubMed ID: 25954623
[TBL] [Abstract][Full Text] [Related]
7. HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.
Tewari M; Kumar A; Mishra RR; Kumar M; Shukla HS
Indian J Surg; 2015 Dec; 77(Suppl 2):447-51. PubMed ID: 26730043
[TBL] [Abstract][Full Text] [Related]
8. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.
Kim Y; Jee S; Kim H; Paik SS; Choi D; Yoo SH; Shin SJ
Oncologist; 2024 May; ():. PubMed ID: 38709907
[TBL] [Abstract][Full Text] [Related]
9. Gastric Cancer: New Drugs - New Strategies.
Schulte N; Ebert MP; Härtel N
Gastrointest Tumors; 2014 May; 1(4):180-94. PubMed ID: 26674336
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.
Samson P; Lockhart AC
J Gastrointest Oncol; 2017 Jun; 8(3):418-429. PubMed ID: 28736629
[TBL] [Abstract][Full Text] [Related]
11. Current status of novel agents in advanced gastroesophageal adenocarcinoma.
Kothari N; Almhanna K
J Gastrointest Oncol; 2015 Feb; 6(1):60-74. PubMed ID: 25642339
[TBL] [Abstract][Full Text] [Related]
12. EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer.
Crees ZD; Shearrow C; Lin L; Girard J; Arasi K; Bhoraskar A; Berei J; Eckburg A; Anderson AD; Garcia C; Munger A; Palani S; Smith TJ; Sreenivassappa SB; Vitali C; David O; Puri N
Ther Adv Med Oncol; 2020; 12():1758835920953731. PubMed ID: 32973931
[TBL] [Abstract][Full Text] [Related]
13. Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers.
Hwang J
J Gastrointest Oncol; 2016 Oct; 7(5):763-770. PubMed ID: 27747090
[TBL] [Abstract][Full Text] [Related]
14. AKT as a Therapeutic Target for Cancer.
Song M; Bode AM; Dong Z; Lee MH
Cancer Res; 2019 Mar; 79(6):1019-1031. PubMed ID: 30808672
[TBL] [Abstract][Full Text] [Related]
15. TET2 Is Downregulated in Early Esophageal Squamous Cell Carcinoma and Promotes Esophageal Squamous Cell Malignant Behaviors.
Wen H; Liu XB; Zhu ZD; Jin S; Gao YJ; Tong Q; Li SB
Dig Dis Sci; 2024 Apr; ():. PubMed ID: 38653944
[TBL] [Abstract][Full Text] [Related]
16. Metabolism-associated molecular classification of gastric adenocarcinoma.
Ye Y; Yang W; Ruan X; Xu L; Cheng W; Zhao M; Wang X; Chen X; Cai D; Li G; Wang Y; Yan F; Lu X; Jiang L
Front Oncol; 2022; 12():1024985. PubMed ID: 36465405
[TBL] [Abstract][Full Text] [Related]
17. Systems biology and OMIC data integration to understand gastrointestinal cancers.
Bispo IMC; Granger HP; Almeida PP; Nishiyama PB; de Freitas LM
World J Clin Oncol; 2022 Oct; 13(10):762-778. PubMed ID: 36337313
[TBL] [Abstract][Full Text] [Related]
18. Network pharmacology and experimental verification based research into the effect and mechanism of Aucklandiae Radix-Amomi Fructus against gastric cancer.
Song S; Zhou J; Li Y; Liu J; Li J; Shu P
Sci Rep; 2022 Jun; 12(1):9401. PubMed ID: 35672352
[TBL] [Abstract][Full Text] [Related]
19. The Frequency of Epidermal Growth Factor Receptor (EGFR) Mutation in Patients with Lung Adenocarcinoma Referred to a Lung Diseases Hospital; A Cross-Sectional Study from Iran.
Mohammadi S; Rezaei M; Shojaeian F; Pourabdollah M; Mohammadi Ziazi L; Seifi S; Doroudinia A; Salimi B; Khosravi A; Farhangnasab MA
Iran J Pathol; 2022; 17(2):159-165. PubMed ID: 35463723
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer
Li H; Guo J; Cheng G; Wei Y; Liu S; Qi Y; Wang G; Xiao R; Qi W; Qiu W
Front Oncol; 2021; 11():564296. PubMed ID: 33987081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
